HER2-Targeted Therapy

  • Phuong Dinh
  • Martine J. PiccartEmail author


The HER2+ subtype of breast cancer represents less than 25 % of incident breast cancers, and traditionally has been regarded as having the more aggressive phenotype, higher recurrence rates, and reduced survival. The HER2 landscape has changed dramatically since the discovery of trastuzumab and have resulted in much improved long-term outcomes for affected patients. HER2 is a validated therapeutic target that remains relevant throughout the disease process. Recently, a number of novel HER2 targeted agents have become available which provide additional treatment options for patients with HER2+ breast cancer. This chapter will discuss the evolution of HER2-targeted therapy, beginning with the initial success of trastuzumab to the controversies that remain, and from there, to the discussion of newer anti-HER2 approaches currently under investigation.


HER2 Breast cancer Trastuzumab Pertuzumab TDM1 Lapatinib 


  1. 1.
    Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82.CrossRefPubMedGoogle Scholar
  2. 2.
    Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–12.CrossRefPubMedGoogle Scholar
  3. 3.
    Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(Suppl 4):S3–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-M, tumour antigen. Nature. 1984;312:513–6.CrossRefPubMedGoogle Scholar
  5. 5.
    King CR, Kraus MH, Aaronsen SA. Amplification of a novel v-erb-related gene in a human mammary carcinoma. Science. 1985;229:974–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Depowski P, Mulford D, Minot P, et al. Comparative analysis of HER-2/neu protein overexpression in breast cancer using paraffin-embedded tissue and cytologic specimens. Mod Pathol. 2002;15:70A.Google Scholar
  7. 7.
    Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0Mo breast cancer: a nationwide population-based study. Clin Cancer Res. 2003; 9:923–30.Google Scholar
  8. 8.
    Press MF, Bernstein PA, Thomas LF, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894–904.CrossRefPubMedGoogle Scholar
  9. 9.
    Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New Engl J Med. 1994;330:1260–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90:1361–70.CrossRefPubMedGoogle Scholar
  11. 11.
    Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90:1346–60.CrossRefPubMedGoogle Scholar
  12. 12.
    Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21:2787–99.CrossRefPubMedGoogle Scholar
  13. 13.
    Franklin MC, Carey KD, Vajdos FF, et al. Insights into ErbB signalling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5:317–28.CrossRefPubMedGoogle Scholar
  14. 14.
    Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66:4426–33.CrossRefPubMedGoogle Scholar
  15. 15.
    Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.CrossRefPubMedGoogle Scholar
  16. 16.
    Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639–48.CrossRefPubMedGoogle Scholar
  17. 17.
    Baselga J, Carbonell X, Castaneda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 2005;23(10):2162–71.CrossRefPubMedGoogle Scholar
  18. 18.
    Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719–26.CrossRefPubMedGoogle Scholar
  19. 19.
    Pegram MD, Konecny GE, O’Callaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004;96(10):739–49.CrossRefPubMedGoogle Scholar
  20. 20.
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.CrossRefPubMedGoogle Scholar
  21. 21.
    Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001;19(10):2587–95.CrossRefPubMedGoogle Scholar
  22. 22.
    Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265–74.CrossRefPubMedGoogle Scholar
  23. 23.
    Hamberg P1, Bos MM, Braun HJ et al. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. Clin Breast Cancer. 2011;11(2):103–13.Google Scholar
  24. 24.
    Pegram MD, Konecny GE, O’Callaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004;96(10):739–49.CrossRefPubMedGoogle Scholar
  25. 25.
    Pegram MD, Finn RS, Arzoo K, et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene. 1997;15(5):537–47.CrossRefPubMedGoogle Scholar
  26. 26.
    Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006;24(18):2786–92.CrossRefPubMedGoogle Scholar
  27. 27.
    Valero V1, Forbes J, Pegram MD, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens BCIRG 007. J Clin Oncol. 2011;10;29(2):149–56.Google Scholar
  28. 28.
    Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003;21(15):2889–95.CrossRefPubMedGoogle Scholar
  29. 29.
    Jahanzeb M, Mortimer JE, Yunus F, et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist. 2002;7(5):410–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001;19(10):2722–30.CrossRefPubMedGoogle Scholar
  31. 31.
    Chan A, Martin M, Untch M, et al. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer. 2006;95(7):788–93.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models. Cancer Chemother Pharmacol. 2002;49:211–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Schaller G, Fuchs I, Gonsch T, et al. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol. 2007;25(22):3246–50.CrossRefPubMedGoogle Scholar
  34. 34.
    Xu L, Song S, Zhu J, et al. Results of a phase II trial of Herceptin® plus Xeloda® in patients with previously untreated HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2004;88(suppl 1):S128.Google Scholar
  35. 35.
    O’Shaughnessy JA, Vukelja S, Marsland T, et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer. 2004;5(2):142–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4:1086–95.CrossRefPubMedGoogle Scholar
  37. 37.
    Wilks S, Puhalla S, O’Shaughnessy J, et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clin Breast Cancer. 2014;14(6):405–12.CrossRefPubMedGoogle Scholar
  38. 38.
  39. 39.
    Wardley A, Antón-Torres A, Pivot X, et al. Trastuzumab plus docetaxel with or without capecitabine in patients with HER2-positive advanced/metastatic breast cancer: first efficacy results from the Phase II MO16419 (CHAT) study. Breast Cancer Res and Treat. 2006;100:abstract 2063.Google Scholar
  40. 40.
    Perez EA, Suman VJ, Rowland KM, et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005;6(5):425–32.CrossRefPubMedGoogle Scholar
  41. 41.
    Polyzos A, Mavroudis D, Boukovinas J, et al. A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER-2. J Clin Oncol (2004 ASCO Annual Meeting Proceedings, Post-Meeting Edition). 2004;22(No 14S):728 (July 15 Supplement).Google Scholar
  42. 42.
    Fountzilas G, Christodoulou C, Tsavdaridis D, et al. Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Cancer Invest. 2004;22(5):655–62.CrossRefPubMedGoogle Scholar
  43. 43.
    Venturini M, Bighin C, Monfardini S, et al. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2006;95(1):45–53.CrossRefPubMedGoogle Scholar
  44. 44.
    Yardley DA, Greco FA, Porter LL, et al. First line treatment with weekly docetaxel, vinorelbine, and trastuzumab in HER2 overexpressing metastatic breast cancer (HER2+ MBC): A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol (ASCO Annual Meeting Proceedings, Post-Meeting Edition). 2004;22(No 14S):643 (July 15 Supplement).Google Scholar
  45. 45.
    Arpino G, Green SJ, Allred DC, et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res. 2004;10(17):5670–6.CrossRefPubMedGoogle Scholar
  46. 46.
    Fornier MN, Seidman AD, Panageas KS, et al. Correlation of ER/PR [immunohistochemistry (IHC)] status to HER2 status by IHC and gene amplification (GA) [fluorescent in-situ hybridization (FISH)], and response rate (RR) for weekly (W) trastuzumab (H) and paclitaxel (T) in metastatic breast cancer (MBC) patients (pts). Proc Am Soc Clin Oncol. 2002;21:56a.Google Scholar
  47. 47.
    Pinto AE, Andre S, Pereira T, et al. C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis. Ann Oncol. 2001;12:525–33.CrossRefPubMedGoogle Scholar
  48. 48.
    Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 2002;20:1467–72.CrossRefPubMedGoogle Scholar
  49. 49.
    Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1993;24:85–95.CrossRefGoogle Scholar
  50. 50.
    Mackey JR, Kaufman B, Clemens M, et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res and Treat. 2006;100:abstract 3.Google Scholar
  51. 51.
    Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808–16.CrossRefPubMedGoogle Scholar
  52. 52.
    Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat. 2007;102(1):43–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Kaufman B1, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33):5529–37.Google Scholar
  54. 54.
    Tripathy D, Slamon DJ, Cobleigh M. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004;22(6):1063–70.CrossRefPubMedGoogle Scholar
  55. 55.
    Fountzilas G, Razis E, Tsavdaridis D, et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer. 2003;4(2):120–5.CrossRefPubMedGoogle Scholar
  56. 56.
    Gelmon KA, Mackey J, Verma S. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer. 2004;52–8:discussion 59-62.Google Scholar
  57. 57.
    Von Minckwitz G, Vogel P, Schmidt M, et al. Trastuzumab treatment beyond progression in patients with HER2 positive metastatic breast cancer—the TBP study (GBG 26/BIG 3-05). In: San Antonio breast cancer symposium, San Antonio, 13th–16th Dec 2007; abstract 4056.Google Scholar
  58. 58.
    Petrelli F, Barni S. A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer. Clin Breast Cancer. 2013;13(2):81–7.CrossRefPubMedGoogle Scholar
  59. 59.
    Jackisch C, Welslau M, Schoenegg W, et al. Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival—results from a prospective, observational study in Germany. Breast. 2014;23(5):603–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Howard A, Burris HA III. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist. 2004;9(suppl 3):10–5.Google Scholar
  61. 61.
    Blackwell KL1, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124–30.Google Scholar
  62. 62.
    Cameron D1, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3):533–43.Google Scholar
  63. 63.
    Lin NU1, Diéras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452–9.Google Scholar
  64. 64.
    Scheuer W, Friess T, Burtscher H, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69:9330–6.CrossRefPubMedGoogle Scholar
  65. 65.
    Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64:2343–6.CrossRefPubMedGoogle Scholar
  66. 66.
    Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28:1138–44.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–71.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Swain SM, Baselga J, Miles D, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25(6):1116–21.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66:4426–33.Google Scholar
  70. 70.
    Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68:9280–90.CrossRefPubMedGoogle Scholar
  71. 71.
    Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29:398–405.CrossRefPubMedGoogle Scholar
  72. 72.
    Krop IE, LoRusso P, Miller KD, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012;30:3234–41.CrossRefPubMedGoogle Scholar
  73. 73.
    Hurvitz SA, Dirix L, Kocsis J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013;31:1157–63.CrossRefPubMedGoogle Scholar
  74. 74.
    Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Amiri-Kordestani L, Blumenthal GM, Xu QC, et al. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014;20:4436–41.CrossRefPubMedGoogle Scholar
  76. 76.
    Krop IE, Kim SB, González-Martín A, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:689–99.CrossRefPubMedGoogle Scholar
  77. 77.
    Paul Anthony Ellis, Carlos H. Barrios, Wolfgang Eiermann et al. Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: primary results from the MARIANNE study. J Clin Oncol. 2015;33(suppl; abstr 507).Google Scholar
  78. 78.
    Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.CrossRefPubMedGoogle Scholar
  79. 79.
    Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER-2 positive breast cancer. N Engl J Med. 2011;365:1273–83.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER-2 positive breast cancer. N Engl J Med. 2011;365:1273–83.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Perez EA, Suman VJ, Davidson NE, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011;29:4491–7.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809–0.Google Scholar
  83. 83.
    Leyland-Jones B, Gelmon K, Ayoub JP, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol. 2003;21:3965–71.CrossRefPubMedGoogle Scholar
  84. 84.
    Pivot X, Romeiu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER-2 positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013;14:741–8.CrossRefPubMedGoogle Scholar
  85. 85.
    Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 2 year versus 1 year of adjuvant trastuzumab for HER2 positive breast cancer (HERA): an open label randomised controlled trial. Lancet. 2013;382:1021–8.CrossRefPubMedGoogle Scholar
  86. 86.
    Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–83.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Vas-Luis I, Ottesen RA, Hughes ME, et al. Outcomes by tumor subtype and treatment pattern in women with small node negative breast cancer: a multi-institutional study. J Clin Oncol. 2014;32:2142–50.Google Scholar
  88. 88.
    Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009;27:5700–6.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol. 2008;26:5697–704.CrossRefPubMedGoogle Scholar
  90. 90.
    Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node negative HER2 positive breast cancer. N Engl J Med. 2015;372:134–41.Google Scholar
  91. 91.
    Piccart-Gebhart M, Holmes AP, Baselga J, et al. First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T then L) or their combination (L & T) in the adjuvant treatment of HER2-positive early breast cancer (EBC). 50th ASCO Annual Meeting. June 2014. Chicago, IL; 2014.Google Scholar
  92. 92.
    Goss PE, Smith IE, O’Shaughnessy J, et al. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(1):88–96.CrossRefPubMedGoogle Scholar
  93. 93.
  94. 94.
    Chan A, Delaloge S, Holmes FA, et al. Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET). J Clin Oncol. 2015;33:(suppl; abstr 508).Google Scholar
  95. 95.
    Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997;151:1523–30.PubMedPubMedCentralGoogle Scholar
  96. 96.
    Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27–31.CrossRefPubMedGoogle Scholar
  97. 97.
    Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841–4.CrossRefPubMedGoogle Scholar
  98. 98.
    Slamon DL, Swain SM, Buyse M, et al. Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive, or high-risk node-negative breast cancer. In: 2013 San Antonio breast cancer symposium. Abstract S1-03. Presented 11 Dec 2014.Google Scholar
  99. 99.
    Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long term clinical benefıt in breast cancer: the CTNEOBC pooled analysis. Lancet. 2014;384:164–72.CrossRefPubMedGoogle Scholar
  100. 100.
    Von Minchwitz G, Untch M, Blohmer JU, et al. Defınition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796–804.CrossRefGoogle Scholar
  101. 101.
    Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377–84.CrossRefPubMedGoogle Scholar
  102. 102.
    Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13:135–44.CrossRefPubMedGoogle Scholar
  103. 103.
    Guarneri V, Frassoldati A, Bottini A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. 2012;30:1989–95.CrossRefPubMedGoogle Scholar
  104. 104.
    Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open label, multicentre, phase 3 trial. Lancet. 2012;379:633–40.CrossRefPubMedGoogle Scholar
  105. 105.
    Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neo- adjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41: an open label, randomised phase 3 trial. Lancet Oncol. 2013;14:1183–92.CrossRefPubMedGoogle Scholar
  106. 106.
    Carey LA, Berry DA, Ollila D, et al. Clinical and translational results of 
CALGB 40601: a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. J Clin Oncol. 2013;31: (suppl; abstr 500).Google Scholar
  107. 107.
    Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32.Google Scholar
  108. 108.
    Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2- positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278–84.Google Scholar
  109. 109.
    Park JW, Liu MC, Yee D, et al. Neratinib plus standard neoadjuvant therapy for high risk breast cancer: efficacy results from the I-SPY 2 trial. 105th AACR annual meeting 2014, April 2014. San Diego, CA; 2014.Google Scholar
  110. 110.
    Rimawi MF, Schiff R, Osborne CK. Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015;66:111–28.CrossRefPubMedGoogle Scholar
  111. 111.
    Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplifıed breast cancer: mechanisms and clinical implications. Crit Rev Oncog. 2012;17:1–16.CrossRefPubMedPubMedCentralGoogle Scholar
  112. 112.
    Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer. 2004;108:334–41.CrossRefPubMedGoogle Scholar
  113. 113.
    Nahta R, Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005;65:11118–28.CrossRefPubMedGoogle Scholar
  114. 114.
    Maroun CR, Rowlands T. The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol Ther. 2014;142:316–38.CrossRefPubMedGoogle Scholar
  115. 115.
    Chen AC, Migliaccio I, Rimawi M, et al. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Res Treat. 2012;134:583–93.CrossRefPubMedPubMedCentralGoogle Scholar
  116. 116.
    Nahta R, Takahashi T, Ueno NT, et al. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004;64:3981–6.CrossRefPubMedGoogle Scholar
  117. 117.
    Giuliano M, Wang YC, Gutierrez C, et al. Parallel upregulation of Bcl2 and estrogen receptor (ER) expression in HER2+ breast cancer patients treated with neoadjuvant lapatinib. Cancer Res. 2012;72:24s (suppl; abstr S5-8).Google Scholar
  118. 118.
    Xia W, Bacus S, Hegde P, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA. 2006;103:7795–800.CrossRefPubMedPubMedCentralGoogle Scholar
  119. 119.
    Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443–6.CrossRefPubMedGoogle Scholar
  120. 120.
    Beano A, Signorino E, Evangelista A, et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med. 2008;6:25.CrossRefPubMedPubMedCentralGoogle Scholar
  121. 121.
    Varchetta S, Gibelli N, Oliviero B, et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 2007;67:11991–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Westmead HospitalWestmeadAustralia
  2. 2.Medicine DepartmentInstitut Jules BordetBruxellesBelgium

Personalised recommendations